Engineered bacterial therapeutics for detecting and treating CRC
- PMID: 38693003
- PMCID: PMC11392429
- DOI: 10.1016/j.trecan.2024.04.001
Engineered bacterial therapeutics for detecting and treating CRC
Abstract
Despite an overall decrease in occurrence, colorectal cancer (CRC) remains the third most common cause of cancer deaths in the USA. Detection of CRC is difficult in high-risk groups, including those with genetic predispositions, with disease traits, or from certain demographics. There is emerging interest in using engineered bacteria to identify early CRC development, monitor changes in the adenoma and CRC microenvironment, and prevent cancer progression. Novel genetic circuits for cancer therapeutics or functions to enhance existing treatment modalities have been tested and verified in vitro and in vivo. Inclusion of biocontainment measures would prepare strains to meet therapeutic standards. Thus, engineered bacteria present an opportunity for detection and treatment of CRC lesions in a highly sensitive and specific manner.
Keywords: detection; engraftment; live bacterial therapeutics; treatment.
Copyright © 2024. Published by Elsevier Inc.
Conflict of interest statement
Declaration of interests A.Z. has a patent for PCT/US18/27998 pending and licensed to Endure Biotherapeutics. A.Z. holds equity in and is the acting Chief Medical Officer of Endure Biotherapeutics. J.H. is a co-founder of GenCirq Inc, which focuses on cancer therapeutics. He is on the Board of Directors and has equity in GenCirq. His spouse is employed part time for the book-keeping and to support employees with Human Resources. The remaining authors have no interests to declare.
Figures


References
-
- Pedrolli DB et al. (2019) Engineering microbial living therapeutics: the synthetic biology toolbox. Trends Biotechnol 37, 100–115 - PubMed
-
- Hamady ZZR et al. (2010) Xylan-regulated delivery of human keratinocyte growth factor-2 to the inflamed colon by the human anaerobic commensal bacterium Bacteroides ovatus. Gut 59, 461–469 - PubMed
-
- Benbouziane B et al. (2013) Development of a stress-inducible controlled expression (SICE) system in Lactococcus lactis for the production and delivery of therapeutic molecules at mucosal surfaces. J. Biotechnol 168, 120–129 - PubMed
Publication types
MeSH terms
Grants and funding
- UH3 TR002968/TR/NCATS NIH HHS/United States
- R01 EB030134/EB/NIBIB NIH HHS/United States
- UL1 TR001442/TR/NCATS NIH HHS/United States
- P30 DK120515/DK/NIDDK NIH HHS/United States
- R01 AI155696/AI/NIAID NIH HHS/United States
- P30 DK063491/DK/NIDDK NIH HHS/United States
- R01 AI141630/AI/NIAID NIH HHS/United States
- T32 DK007202/DK/NIDDK NIH HHS/United States
- R01 AI163483/AI/NIAID NIH HHS/United States
- UG3 TR002968/TR/NCATS NIH HHS/United States
- U01 CA265719/CA/NCI NIH HHS/United States
- P30 CA014195/CA/NCI NIH HHS/United States